Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ELC

Other · developed by Insmed

Phase 3 Most advanced trial (none active)
INSM Developer
1 Registered trials

What is ELC?

ELC is an empty liposome control, a liposome carrier without an active drug payload, given by nebulized inhalation. It is studied in nontuberculous mycobacterial infections, including Mycobacterium avium-intracellulare infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Empty liposome control
Drug type
Other
Therapy area
Infectious disease
Developer
Insmed Incorporated (INSM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
R4QQ5YK78D

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04677543 Phase 3 Mycobacterium Infections, Nontuberculous Completed INSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mycobacterium Infections, Nontuberculous

More from Insmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INSM page.

Follow INSM, the company behind ELC

See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INSM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.